Tim Chiang

In a report published Wednesday, CRT Capital analyst Tim Chiang increased his price target on Buy-rated shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) to $220 from a previous $180 following Tuesday's conference call, which highlighted strong fundamentals and the strategic rationale...

CRT Capital raised its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from $170 to $180 and maintained a Buy rating. Analyst Tim Chiang noted that the company is “well positioned for growth in the specialty pharma industry, focused in the areas of dermatology and eye care in...

CRT Capital upgraded Akorn, Inc. (NASDAQ: AKRX) from Fair Value to Buy with a $46 price target. Analyst Tim Chiang believed “the recent sell off in AKRX shares post 3Q results creates a potential buying opportunity, based on our view that the Company will benefit from solid pricing trends...